A Randomized Multicenter Phase Ib/II Study to Assess the Safety and the Immunological Effect of Chemoradiation Therapy (CRT) in Combination With Pembrolizumab (MK-3475) Compared to CRT Alone in Patients With Resectable or Borderline Resectable Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Sep 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
- 06 Jun 2017 Interim safety results (n=22) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.